Sodium dihydrogen phosphate anhydrous 1.936g effervescent tablets
Available from pharmacies, supermarkets, and retail outlets
Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Sodium dihydrogen phosphate on the MHRA register
Phosphate Sandoz effervescent tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 29 studies.
1946–2026
Showing all 29 studies, sorted by most relevant.
J. Jerphagnon, S. K. Kurtz
Physical Review B, 1970
W. P. Mason
Physical Review, 1946
Mohammed Taghi Zafarani-Moattar, Rahmat Sadeghi
Fluid Phase Equilibria, 2001
M. T. Zafarani-Moattar, Rahmat Sadeghi
Fluid Phase Equilibria, 2002
X. Ren, Jiangshi Zhang, Hongfu Jia
Process Safety and Environmental Protection, 2024
Liyun Pu, Jiaze Wang, Kevin Seng Hong Pang, et al.
Construction and Building Materials, 2024
Pushpanjali Singh, A. K. Sharma, Pawan Kumar, et al.
Russian Journal of Inorganic Chemistry, 2024
Luis Caballero-Sanchez, P. E. Lázaro-Mixteco, Ana Alejandra Vargas-Tah, et al.
Journal of Chemical & Engineering Data, 2024
Sunday G. Borisade, Seun S. Owoeye, Kehinde V. Ajayi, et al.
Hybrid Advances, 2024
The ever-increasing generation of waste glass, poses a major environmental challenges due to its large volume and limited recycling options. This research explores a novel sustainable approach to repurposing this waste by transforming it into silicate based bioactive glass-ceramics (SBGCs). The glass waste was recycled into powder form and homogeneously mixed with sodium dihydrogen orthophosphate (NaH 2 PO 4 ) in the step of 2, 4, 6, 8 and 10 wt % respectively with addition of organic binder and sintered by microwave irradiation approach. The obtained SBGCs were then characterized for its phase constituents, microstructure, physical, mechanical, and in-vitro bioactivity behaviour. The results showed that the samples exhibited considerable density and porosity while both the micro-hardness and compressive strength decreased with increased phosphate content. Sample SLP2% showed optimum hardness and compressive strength of 7.3 GPa and 87 MPa respectively. Combeite was obtained as the major phase while wollastonite and quartz were also detected. The developed SBGCs also showed increased hydroxyapatite (HA) formation after immersion in simulated body fluid (SBF) and displayed good antibacterial capacity when reacted with four bacteria strains. The results obtained indicate that the developed SBGCs might be considered a potential candidate for biomedical applications. However, sample SLP8% is the best sample to serve as bioactive glass-ceramics considering the combination of its high HA and good CHA formation, besides its considerable density and mechanical properties.
Abstract licence: CC BY
DONG Xuan, LU Ruqing, PANG Xiaoyang, LÜ Jiaping, YU Jinghua, WANG Yunna, LI Hongjuan, ZHANG Shuwen
Shipin Kexue, 2025
Sodium tripolyphosphate (STPP), sodium dihydrogen phosphate (SHP), disodium hydrogen phosphate (DSP), sodium hexametaphosphate (SHMP), and tetrasodium pyrophosphate (SPP) were employed for the moist-heat phosphorylation of whey protein isolate (WPI90) under varying temperatures and pH conditions. Phosphorylated proteins with stronger heat resistance were selected to determine their solubility, free sulfhydryl content, surface hydrophobicity, secondary structure, sodium, phosphorus, and calcium contents. Furthermore, they underwent ultra-high temperature (UHT, 135 ℃) processing followed by evaluation of their thermal stability indicators, including centrifugal precipitation rate, viscosity, and particle size as well as their solubility and structure. Commercial heat-stable whey protein was used as control. The results revealed that phosphorylation at 75 ℃ led to an increase in the content of free sulfhydryl groups and a decrease in surface hydrophobicity. The incorporation of phosphates increased the sodium and phosphorus contents while reducing both soluble and total calcium contents, with SPP and SHP resulting in the lowest soluble calcium levels (< 3 mg/g). Fourier transform infrared spectroscopy (FTIR) indicated alterations in protein secondary structure, characterized by a general decrease in β-sheet content and an increase in β-turn content. Phosphorylation at 85 ℃ increased the random coil content. All phosphates except DSP enhanced the thermal stability of whey protein at pH 7.0 and different temperatures (75, 80, and 85 ℃), preventing flocculation of whey protein after UHT treatment. The SHMP-modified protein demonstrated the lowest centrifugal precipitation rate and apparent viscosity after UHT treatment, with an overall particle size below 15 µm. Moreover, phosphorylation with SPP, STPP, and SHP at 75 ℃ improved the solubility of WPI90 to different extents, while phosphorylation with SHMP did not. For both 75 and 80 ℃, SPP phosphorylation resulted in the highest solubility of WPI90. In conclusion, this study demonstrates that moist-heat phosphorylation effectively modifies the structure and functionality of whey protein while influencing the salt ion contents in the protein system. Specifically, the addition of SHMP under neutral pH conditions significantly enhances the thermal stability of whey protein, being of guiding significance for the UHT processing of whey protein concentrate.
Abstract licence: CC BY-SA
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
44 found
Half-life
Not available
Mechanism
Sodium phosphate is thought to work by increasing the amount of solute present i…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1-3h
[A19448]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 781 interactions
[L799]
Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma .
[A19449]
Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients .
[A19448]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A19448]
Proteins that transport this drug across cell membranes
PMID:11009570 PMID:16790504 PMID:17494632 PMID:19726692 PMID:7929240 PMID:8041748
May play a role in extracellular matrix and cartilage calcification as well as in vascular calcification .
PMID:11009570
Essential for cell proliferation but this function is independent of its phosphate transporter activity PMID:19726692
PMID:12205090 PMID:15955065 PMID:16790504 PMID:17494632 PMID:22327515 PMID:28722801 PMID:30704756
Plays a critical role in the determination of bone quality and strength by providing phosphate for bone mineralization (By similarity). Required to maintain normal cerebrospinal fluid phosphate levels (By similarity). Mediates phosphate-induced calcification of vascular smooth muscle cells (VCMCs) and can functionally compensate for loss of SLC20A1 in VCMCs (By similarity)
PMID:12324554 PMID:20335586 PMID:26047794 PMID:8327470
The cotransport has a Na(+):Pi stoichiometry of 3:1 and is electrogenic (By similarity)
PMID:11880379
The cotransport has a Na(+):Pi stoichiometry of 2:1 and is electroneutral (By similarity)
ATC A06AG01
ATC V03AG05
ATC A06AD17
ATC B05XA09
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Sodium phosphate, monobasic
Matched from: Sodium dihydrogen phosphate
Additional database identifiers
Drugs Product Database (DPD)
293
Drugs Product Database (DPD)
4753
Drugs Product Database (DPD)
4759
Drugs Product Database (DPD)
20445
ChemSpider
22626
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10946
GeneCards
SLC20A1
UniProt Accession
S20A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10947
GeneCards
SLC20A2
UniProt Accession
S20A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11019
GeneCards
SLC34A1
UniProt Accession
NPT2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11020
GeneCards
SLC34A2
Guide to Pharmacology
1136
UniProt Accession
NPT2B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:20305
GeneCards
SLC34A3
UniProt Accession
NPT2C_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure
Linked open data from Wikidata (Q415877), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.